Table III.
Clinicopathological characteristics of patients with primary breast cancer and expression of CADM1 and CADM4.
| CADM1, n (%) | CADM4, n (%) | |||||
|---|---|---|---|---|---|---|
| Characteristics | + (n=48) | − (n=160) | P-value | + (n=42) | − (n=166) | P-value |
| Age (years) | 0.738 | 0.857 | ||||
| <50 | 20 (42) | 62 (39) | 14 (33) | 60 (36) | ||
| ≥50 | 28 (58) | 98 (61) | 28 (67) | 106 (64) | ||
| Metastatic lymph nodes | 0.137 | 0.083 | ||||
| 0 | 34 (71) | 94 (59) | 30 (71) | 99 (60) | ||
| 1–3 | 12 (25) | 44 (28) | 11 (26) | 44 (27) | ||
| ≥4 | 2 (4) | 22 (13) | 1 (3) | 23 (13) | ||
| Lymphovascular invasion | 0.617 | 0.863 | ||||
| − | 21 (44) | 63 (39) | 17 (40) | 70 (42) | ||
| + | 27 (56) | 97 (61) | 25 (60) | 96 (58) | ||
| Hormone status | 0.570 | 0.004 | ||||
| +/+ or +/− | 38 (79) | 119 (74) | 24 (57) | 133 (80) | ||
| −/− | 10 (21) | 41 (26) | 18 (43) | 33 (20) | ||
| Her2 | 0.126 | 1 | ||||
| Positive | 1 (2) | 15 (9) | 3 (7) | 13 (8) | ||
| Negative | 47 (98) | 145 (91) | 39 (93) | 153 (92) | ||
| Triple negative | 0.367 | 0.008 | ||||
| Yes | 10 (21) | 23 (14) | 13 (31) | 20 (12) | ||
| No | 38 (79) | 137 (86) | 29 (69) | 146 (88) | ||
| pT stage | 0.041 | 0.039 | ||||
| 1 | 35 (73) | 81 (50) | 31 (74) | 83 (50) | ||
| 2 | 13 (27) | 70 (44) | 10 (24) | 75 (45) | ||
| 3 | 0 | 3 (2) | 0 | 3 (2) | ||
| 4 | 0 | 6 (4) | 1 (2) | 5 (3) | ||
| Pathological stage | 0.038 | 0.029 | ||||
| I | 26 (54) | 56 (35) | 24 (57) | 58 (35) | ||
| II | 22 (46) | 98 (61) | 17 (41) | 103 (62) | ||
| III | 0 | 6 (4) | 1 (2) | 5 (3) | ||
| Local recurrence | 1 | 1 | ||||
| − | 47 (98) | 155 (97) | 41 (98) | 161 (97) | ||
| + | 1 (2) | 5 (3) | 1 (2) | 5 (3) | ||
| Remote recurrence | 0.372 | 0.314 | ||||
| − | 46 (96) | 146 (91) | 37 (88) | 156 (94) | ||
| + | 2 (4) | 14 (9) | 5 (12) | 10 (6) | ||
P-values were calculated using Fisher's exact test for age, lymphovascular invasion, hormone status, her2, triple negative, local recurrence and remote recurrence or a χ2 test for metastatic lymph node, pT stage and pathological stage. HER2, Human epidermal growth factor receptor 2; CADM, cell adhesion molecule; hormone status, estrogen and progesterone receptor status; pT, pathological tumor stage.